Immix Biopharma jumps on positive trial data for protein disorder therapy

Immix Biopharma

06/11/2023 17:44

** Shares of therapy developer Immix Biopharma  IMMX.O  rise
13.5% to $4.05
    ** Co says its therapy NXC-201 showed a 100% overall
response rate in AL amyloidosis patients with a median 6 lines
of prior therapy
    ** AL amyloidosis is a protein misfolding and metabolism
disorder which can cause organ dysfunction and, eventually death
    ** Including session moves, stock up 86% YTD

 (Reporting by Christy Santhosh)
 ((Christy.Santhosh@thomsonreuters.com))